Summary statement on screening for prostate cancer in Europe
暂无分享,去创建一个
J. Borrás | H. Grönberg | M. Eklund | H. D. de Koning | X. Castells | V. Nelen | E. Heijnsdijk | M. Roobol | I. Lansdorp-Vogelaar | M. Graefen | J. Espinàs | F. Recker | C. Bangma | T. D. de Carvalho | P. J. Leeuwen | Pieter Vandenbulcke
[1] E. Schaeffer,et al. Active Surveillance for Prostate Cancer. , 2017, JAMA.
[2] P. Stattin,et al. Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden , 2017, JAMA oncology.
[3] David Gillatt,et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.
[4] J. Gohagan,et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years , 2017, Cancer.
[5] A Hayen,et al. The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer. , 2016, The Journal of urology.
[6] P. Carroll,et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines , 2016, Nature Reviews Urology.
[7] Martin Eklund,et al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. , 2015, The Lancet. Oncology.
[8] J. Fütterer,et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. , 2015, European urology.
[9] M. Cooperberg,et al. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. , 2015, European urology.
[10] John W. Scott,et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. , 2015, European urology.
[11] H. Brenner,et al. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme. , 2015, European journal of cancer.
[12] M. Cooperberg,et al. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.
[13] S. Taneja,et al. Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. , 2015, The Journal of urology.
[14] S. Eggener,et al. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] John T. Wei,et al. The prostate health index selectively identifies clinically significant prostate cancer. , 2015, The Journal of urology.
[16] H. D. de Koning,et al. Screening for prostate cancer in the US? Reduce the harms and keep the benefit , 2015, International journal of cancer.
[17] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[18] Ruth Etzioni,et al. Is prostate cancer screening cost‐effective? A microsimulation model of prostate‐specific antigen‐based screening for British Columbia, Canada , 2014, International journal of cancer.
[19] Mohammad Hassan Murad,et al. Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.
[20] M. Stockler,et al. Risk assessment to guide prostate cancer screening decisions: a cost‐effectiveness analysis , 2013, The Medical journal of Australia.
[21] P. Scardino,et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study , 2013, BMJ : British Medical Journal.
[22] E. Steyerberg,et al. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. , 2013, European urology.
[23] Tobias Nordström,et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. , 2013, European urology.
[24] Ruth Etzioni,et al. Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies , 2013, Annals of Internal Medicine.
[25] H. D. de Koning,et al. Quality-of-life effects of prostate-specific antigen screening. , 2012, The New England journal of medicine.
[26] H. Sox. Quality of life and guidelines for PSA screening. , 2012, The New England journal of medicine.
[27] M. Roobol,et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. , 2012, European urology.
[28] Ruth Etzioni,et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy , 2012, Cancer Causes & Control.
[29] D. Easton,et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening , 2011, British Journal of Cancer.
[30] J. Hugosson,et al. The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population-based prostate cancer screening trial. , 2011, European journal of cancer.
[31] G. Andriole,et al. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. , 2011, The Journal of urology.
[32] T. Wilt,et al. Screening for prostate cancer: an updated Cochrane systematic review , 2011, BJU international.
[33] F. Hamdy,et al. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. , 2010, European journal of cancer.
[34] P. Scardino,et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study , 2010, BMJ : British Medical Journal.
[35] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[36] Angela Mariotto,et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.
[37] M. Roobol,et al. A COMMENT ON PROSTATE CANCER SCREENING IN THE PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER SCREENING TRIAL: UPDATE ON FINDINGS FROM THE INITIAL FOUR ROUNDS OF SCREENING IN A RANDOMIZED TRIAL , 2009, BJU international.
[38] J. Gohagan,et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial , 2008, BJU international.
[39] Wadih Arap,et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.
[40] J. Habbema,et al. Five‐year follow‐up of health‐related quality of life after primary treatment of localized prostate cancer , 2005, International journal of cancer.
[41] M. Roobol,et al. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). , 2005, Urology.
[42] Harry J de Koning,et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.
[43] F. Hamdy,et al. Screening for Prostate Cancer , 2006 .
[44] A. Auvinen,et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. , 2015, Journal of the National Cancer Institute.
[45] D. Parekh,et al. The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices. , 2015, Reviews in urology.
[46] Ali Amin Al Olama,et al. The genetic epidemiology of prostate cancer and its clinical implications , 2014, Nature Reviews Urology.
[47] T. Tammela,et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.
[48] G. Andriole. Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer , 2013 .
[49] Monique J. Roobol,et al. Mortality Results from a Randomized ProstateCancer Screening Trial , 2009 .
[50] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[51] H. D. de Koning,et al. Prostate cancer diagnosis: the impact on patients' mental health. , 2006, European journal of cancer.
[52] Yair Lotan,et al. Systematic review of complications of prostate biopsy. , 2013, European urology.